

JAN 2 2005

K 043336

**IBt**

2 December 2004

CONFIDENTIAL

Page 16 of 16

Title: **Premarket Notification: Traditional 510(k) – OptiStrand™****510(k) SUMMARY****Applicant /Manufacturing Site:**

IBt s.a.

Zone Industrielle C

7180 Seneffe – Belgium

Tel: (+32) 64 / 520 811

Fax: (+32) 64 / 520 801

Establishment Registration Number: 9031509 (IBt s.a.)

Contact Person IBt s.a.: Sylviane Berger, Management Representative

E-mail: sberger@brachytherapy.be and

FDA@ibt4seeds.com

**Official Correspondent:**

IBt, Inc.

6000 Live Oak Parkway, Suite 107

Norcross, GA 30093

Tel: (770) 582 0662

Fax: (770) 582 0657

Establishment Registration Number: 9035105 (IBt, Inc.)

Contact Person IBt, Inc.:

Ruth Feicht, Regulatory

E-mail:

rfeicht@ibt4seeds.com and

FDA@ibt4seeds.com

**Device Information**

Trade Name:

OptiStrand<sup>103</sup> (OptiStrand™ is a Trademark of IBt s.a.)

Model Number:

1032S

Common Name of Device

Sealed Source; seed; interstitial implant

Description:

OptiStrand<sup>103</sup> implants are OptiSource™ seeds (#K040766) linked together with a spacer or spacers to create a multi-seed sourcetrain.**Type of 510(k) Submission:** Traditional**Classification Information**

Classification: Radionuclide Brachytherapy Source

Class of Device: 21 CFR 892.5730, Class II

Product Code: 90-KXX

**Intended Use**

OptiStrand<sup>103</sup> implants are indicated for interstitial implantation of select localized tumors with low to moderate radiosensitivity. They are used either as primary treatment for tumors such as those of the head, lung, neck, pancreas, breast, cervix, prostate, and unresectable tumors, or for residual disease after excision of the primary tumor. OptiStrand<sup>103</sup> implants are indicated for use concurrent with or at the completion of other treatment modalities, such as external beam radiation therapy or chemotherapy.



JAN 21 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

IBt, s.a.  
% Ms. Ruth Feicht  
Regulatory  
IBt, Inc.  
6000 Live Oak Parkway, Suite 107  
NORCROSS GA 30093

Re: K043336  
Trade/Device Name: OptiStrand<sup>103</sup> (OptiStrand<sup>TM</sup>  
is a Trademark of IBt, s.a.)  
Regulation Number: 21 CFR 892.5730  
Regulation Name: Radionuclide  
brachytherapy source  
Regulatory Class: II  
Product Code: 90 KXX  
Dated: December 2, 2004  
Received: December 8, 2004

Dear Ms. Feicht:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number (if Known):

K043336Device Name: OptiStrand<sup>103</sup>

Indications For Use:

OptiStrand<sup>103</sup> implants are indicated for interstitial implantation of select localized tumors with low to moderate radiosensitivity. They are used either as primary treatment for tumors such as those of the head, lung, neck, pancreas, breast, cervix, prostate, and unresectable tumors, or for residual disease after excision of the primary tumor. OptiStrand<sup>103</sup> implants are indicated for use concurrent with or at the completion of other treatment modalities, such as external beam radiation therapy or chemotherapy.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use

☒

OR

Over-The-Counter-Use

Nancye Brydon  
(Division Sign-Off)Division of Reproductive, Abdominal,  
and Radiological Devices

510(k) Number

K043336